Stocks and Investing Stocks and Investing
Thu, November 3, 2022
Wed, November 2, 2022

Liisa Bayko Upgraded (BCRX) to Buy and Held Target at $16 on, Nov 2nd, 2022


Published on 2024-10-27 23:49:50 - WOPRAI, Liisa Bayko
  Print publication without navigation


Liisa Bayko of Evercore ISI Group, Upgraded "BioCryst Pharmaceuticals, Inc." (BCRX) to Buy and Held Target at $16 on, Nov 2nd, 2022.

Liisa has made no other calls on BCRX in the last 4 months.



There are 2 other peers that have a rating on BCRX. Out of the 2 peers that are also analyzing BCRX, all agree with Liisa's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Justin Kim of "Oppenheimer" Downgraded from Buy to Hold on, Monday, August 8th, 2022
  • Gena Wang of "Barclays" Maintained at Hold with Increased Target to $14 on, Friday, August 5th, 2022